Story
China Literature Repurchases 200,000 Shares for HK$3.94 Million
Summary
The online literature platform executed the share buyback on September 24, paying between HK$19.52 and HK$19.90 per share, according to a company filing.
China Literature Limited (00772.HK) has repurchased 200,000 of its own shares on the open market for a total consideration of approximately HK$3.94 million, according to a recent stock exchange filing.
Transaction Details
The company announced that the transaction was completed on September 24, 2026. This move is part of the company's ongoing capital management strategy.
Key figures from the buyback include:
- Total Shares Repurchased: 200,000
- Total Cost: HK$3,936,400
- Price Range: HK$19.52 to HK$19.90 per share
AdMarket Significance
Share repurchase programs are a common tool for companies to return capital to shareholders. Such actions can signal to the market that management believes the company's stock is undervalued.
By reducing the number of outstanding shares, buybacks can have an accretive effect on earnings per share (EPS), a key metric for investors. This can potentially enhance shareholder value over time.
Read next
More on Stocks
Yujian Group Repurchases 96,500 Shares for HK$406,300
Yujian Group Holdings Limited (HKEX: 02408) announced it has bought back 96,500 of its own shares for a total consideration of HK$406,300, according to a company filing on September 24.
Spring REIT Repurchases 80,000 Units for HK$106,600
Spring REIT, a Hong Kong-listed real estate investment trust, announced it bought back 80,000 of its own fund units on September 24 for a total consideration of HK$106,600.
China Shenhua to Pay Final Dividend of RMB 0.98 Per Share on November 23
China Shenhua Energy Co., Ltd. (SEHK: 01088) has announced it will distribute a final dividend of RMB 0.98 per share, with the payment scheduled for November 23, 2026.
Bioperfectus Technologies Secures Chinese Approval for Hepatitis C and Chikungunya Test Kits
Jiangsu Bioperfectus Technologies (688399.SH) has received registration certificates from China's National Medical Products Administration for two new nucleic acid detection kits, expanding its portfolio in the in-vitro diagnostics sector.